Combination of human endothelial colony-forming cells and mesenchymal stromal cells exert neuroprotective effects in the growth-restricted newborn.
Kirat K ChandJatin PatelS T BjorkmanSeen-Ling SimStephanie M MillerElliot J TeoLara JonesJane SunPaul B ColditzKiarash KhosrotehraniJulie A WixeyPublished in: NPJ Regenerative medicine (2021)
The foetal brain is particularly vulnerable to the detrimental effects of foetal growth restriction (FGR) with subsequent abnormal neurodevelopment being common. There are no current treatments to protect the FGR newborn from lifelong neurological disorders. This study examines whether pure foetal mesenchymal stromal cells (MSC) and endothelial colony-forming cells (ECFC) from the human term placenta are neuroprotective through modulating neuroinflammation and supporting the brain vasculature. We determined that one dose of combined MSC-ECFCs (cECFC; 106 ECFC 106 MSC) on the first day of life to the newborn FGR piglet improved damaged vasculature, restored the neurovascular unit, reduced brain inflammation and improved adverse neuronal and white matter changes present in the FGR newborn piglet brain. These findings could not be reproduced using MSCs alone. These results demonstrate cECFC treatment exerts beneficial effects on multiple cellular components in the FGR brain and may act as a neuroprotectant.
Keyphrases
- white matter
- cerebral ischemia
- endothelial cells
- resting state
- induced apoptosis
- functional connectivity
- multiple sclerosis
- bone marrow
- cell cycle arrest
- gestational age
- subarachnoid hemorrhage
- preterm infants
- mesenchymal stem cells
- traumatic brain injury
- induced pluripotent stem cells
- endoplasmic reticulum stress
- lipopolysaccharide induced
- inflammatory response
- smoking cessation
- electronic health record
- cognitive impairment